At the news
? NEUTRALIMPACT 6/10 8-K filed Apr 16, 2026 at 17:06 ET
Revolution Medicines raised approximately $1.65 billion through a public offering of 12.15 million common shares at $142.00 per share, alongside a separate $500 million convertible note offering. The proceeds will fund R&D, commercialization of product candidates, and general corporate purposes.
- Company issued 12,147,887 shares of common stock (10,563,381 base + 1,584,506 option) at $142.00 per share
- Net proceeds from equity offering estimated at $1.65 billion after underwriting discounts and expenses
- Concurrent $500 million offering of 0.50% convertible senior notes due 2033
- Proceeds to be used for R&D, potential commercialization of product candidates, general corporate purposes, and potential acquisitions
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access